GlassScriptPhysician profile
Jennifer M Mcmonigle
NPI 1912958802
$19,942.95
in general payments reported to CMS, 2019-2025
31 companies · $445 in 2025
The $445 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2021: $1,251 · 2022: $1,445 · 2023: $16K · 2024: $365 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $16K · Food and Beverage: $1,466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $15,636.65 |
| Food and Beverage | $1,466.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $15,820.83 | 2022-2023 | Neurostar Tms Therapy System |
| Abbvie INC. | $1,333.18 | 2021-2025 | |
| Allergan, INC. | $780.25 | 2019-2022 | |
| Pfizer INC. | $288.21 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $242.07 | 2022 | |
| Genzyme Corporation | $214.86 | 2021-2023 | |
| Amgen INC. | $128.34 | 2022 | |
| Biogen, INC. | $120.79 | 2021-2023 | Vumerity |
| Lundbeck LLC | $108.24 | 2023-2025 | Vyepti, Rexulti |
| Amneal Pharmaceuticals LLC | $98.87 | 2022-2023 | Rytary |
| Biohaven Pharmaceuticals, INC. | $88.15 | 2021 | |
| Novartis Pharmaceuticals Corporation | $80.22 | 2021-2023 | |
| Catalyst Pharmaceuticals, INC. | $75.65 | 2023-2025 | Firdapse |
| Eisai INC. | $60.06 | 2021 | |
| Lilly USA, LLC | $46.49 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $45.92 | 2021 | |
| Janssen Pharmaceuticals, INC | $44.79 | 2022-2025 | Spravato |
| Neurelis, INC. | $37.18 | 2022 | |
| Globus Medical, INC. | $34.42 | 2025 | Senza |
| Merz Pharmaceuticals, LLC | $31.38 | 2021 | |
| Alnylam Pharmaceuticals INC. | $27.80 | 2024 | Amvuttra |
| Sk Life Science, INC. | $27.62 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $27.52 | 2025 | Rexulti |
| Alexion Pharmaceuticals, INC. | $27.33 | 2019 | |
| Supernus Pharmaceuticals, INC. | $26.52 | 2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $23.89 | 2022 | |
| Tanabe Pharma America, INC. | $23.85 | 2023 | |
| Arbor Pharmaceuticals, INC. | $21.12 | 2021 | |
| Impel Pharmaceuticals LLC | $19.72 | 2025 | Trudhesa |
| Celgene Corporation | $19.24 | 2021 | |
| Currax Pharmaceuticals LLC | $18.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Mcmonigle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.